| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Review |
Authors' Affiliation: Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
Requests for reprints: Phillip A. Dennis, National Cancer Institute/Naval Medical Oncology, Building 8, Room 5101, 8901 Wisconsin Avenue, Bethesda, MD 20889. Phone: 301-496-0901; Fax: 301-496-0047; E-mail: pdennis{at}nih.gov.
The phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Genetic alterations and biochemical activation of the pathway are frequent events in preneoplastic lesions and advanced cancers and often portend a poor prognosis. Thus, inhibition of the PI3K/Akt/mTOR pathway is an attractive concept for cancer prevention and/or therapy. Inhibitors of individual components, such as PI3K, PDK-1, Akt, and mTOR, are being developed at a rapid pace and have promise for improving the care of cancer patients. Here, we review the published data on inhibitors of the pathway and discuss relevant issues, such as the complex regulation of the pathway, the design of clinical trials, and the likelihood of finding a therapeutic index when targeting such a critical signaling pathway.
This article has been cited by other articles:
|
|
 |
|
  C. Lu, M. C. Willingham, F. Furuya, and S.-y. Cheng Activation of Phosphatidylinositol 3-Kinase Signaling Promotes Aberrant Pituitary Growth in a Mouse Model of Thyroid-Stimulating Hormone-Secreting Pituitary Tumors Endocrinology, July 1, 2008; 149(7): 3339 - 3345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Caporali, L. Levati, G. Starace, G. Ragone, E. Bonmassar, E. Alvino, and S. D'Atri AKT Is Activated in an Ataxia-Telangiectasia and Rad3-Related-Dependent Manner in Response to Temozolomide and Confers Protection against Drug-Induced Cell Growth Inhibition Mol. Pharmacol., July 1, 2008; 74(1): 173 - 183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Hecht Current and emerging therapies for metastatic colorectal cancer: Applying research findings to clinical practice Am. J. Health Syst. Pharm., June 1, 2008; 65(11_Supplement_4): S15 - S21. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. H. Lu, W. Wu, B. Dave, B. M. Slomovitz, T. W. Burke, M. F. Munsell, R. R. Broaddus, and C. L. Walker Loss of Tuberous Sclerosis Complex-2 Function and Activation of Mammalian Target of Rapamycin Signaling in Endometrial Carcinoma Clin. Cancer Res., May 1, 2008; 14(9): 2543 - 2550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Voisset, S. Lopez, P. Dubreuil, and P. De Sepulveda The tyrosine kinase FES is an essential effector of KITD816V proliferation signal Blood, October 1, 2007; 110(7): 2593 - 2599. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-M. Hong, Y.-L. Chen, Y.-Y. Wu, A. Yuan, Y.-C. Chao, Y.-C. Chung, M.-H. Wu, S.-C. Yang, S.-H. Pan, J.-Y. Shih, et al. Targeting Neuropilin 1 as an Antitumor Strategy in Lung Cancer Clin. Cancer Res., August 15, 2007; 13(16): 4759 - 4768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Crowell, V. E. Steele, and J. R. Fay Targeting the AKT protein kinase for cancer chemoprevention Mol. Cancer Ther., August 1, 2007; 6(8): 2139 - 2148. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Kopelovich, J. R. Fay, C. C. Sigman, and J. A. Crowell The Mammalian Target of Rapamycin Pathway as a Potential Target for Cancer Chemoprevention Cancer Epidemiol. Biomarkers Prev., July 1, 2007; 16(7): 1330 - 1340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Martin and R. C. Baxter Expression of Insulin-Like Growth Factor Binding Protein-2 by MCF-7 Breast Cancer Cells Is Regulated through the Phosphatidylinositol 3-Kinase/AKT/Mammalian Target of Rapamycin Pathway Endocrinology, May 1, 2007; 148(5): 2532 - 2541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Fecher, S. D. Cummings, M. J. Keefe, and R. M. Alani Toward a Molecular Classification of Melanoma J. Clin. Oncol., April 20, 2007; 25(12): 1606 - 1620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Granville, N. Warfel, J. Tsurutani, M. C. Hollander, M. Robertson, S. D. Fox, T. D. Veenstra, H. J. Issaq, R. I. Linnoila, and P. A. Dennis Identification of a Highly Effective Rapamycin Schedule that Markedly Reduces the Size, Multiplicity, and Phenotypic Progression of Tobacco Carcinogen-Induced Murine Lung Tumors Clin. Cancer Res., April 1, 2007; 13(7): 2281 - 2289. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Diehl, E. T. Keller, and K. M. Woods Ignatoski Why should we still care about oncogenes? Mol. Cancer Ther., February 1, 2007; 6(2): 418 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Schaefer, W. Tsalastra, A. Babelova, M. Baliova, J. Minnerup, L. Sorokin, H.-J. Grone, D. P. Reinhardt, J. Pfeilschifter, R. V. Iozzo, et al. Decorin-Mediated Regulation of Fibrillin-1 in the Kidney Involves the Insulin-Like Growth Factor-I Receptor and Mammalian Target of Rapamycin Am. J. Pathol., January 1, 2007; 170(1): 301 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mateo-Lozano, P. C. Gokhale, V. A. Soldatenkov, A. Dritschilo, O. M. Tirado, and V. Notario Combined Transcriptional and Translational Targeting of EWS/FLI-1 in Ewing's Sarcoma. Clin. Cancer Res., November 15, 2006; 12(22): 6781 - 6790. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Garcia-Morales, E. Hernando, E. Carrasco-Garcia, M. P. Menendez-Gutierrez, M. Saceda, and I. Martinez-Lacaci Cyclin D3 is down-regulated by rapamycin in HER-2-overexpressing breast cancer cells. Mol. Cancer Ther., September 1, 2006; 5(9): 2172 - 2181. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
